Status: Recruiting
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
An open-label, single-arm, multicenter, prospective clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma
Participants needed: 100
Trial details
Age: 18-90Biological sex: AllType: ObservationalSponsor: Zhengzhou UniversityUpdated: Aug 18, 2022Locations: 1Duration: 2 Years
Eligibility criteria
Age 18-70, ECOG score 0-2; [+4]
Patients with definite neuropathy or psychosis, including dementia or seizures,... [+10]